Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer

A Vanderbilt Cancer Center phase II trial

B. Nicholson, D. Paul, Y. Shyr, M. Garrett, K. R. Hande, D. H. Johnson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenously over 30 to 60 minutes followed by 5- fluorouracil 350 mg/m2 via intravenous push on days 1 to 3 every 28 days for six cycles. Eight patients were chemotherapy naive. Of 47 previously treated women, 30 had received anthracyclines. Fifty-two patients were evaluable for response. Three (6%) experienced a complete response and 24 (46%) had a partial response, for an overall response rate of 52%. Patients previously exposed to doxorubicin had a response rate similar to those with no prior doxorubicin exposure (50% v 54%, respectively). The median duration of response was 8.6 months and median survival was 17.7 months. Toxicity was modest, with grade 3 or 4 neutropenia observed in only 5.5% (15 of 274) of cycles. Preliminary results indicate that paclitaxel/5- fluorouracil/leucovorin is an active, well-tolerated regimen for treating metastatic breast cancer.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number4 SUPPL. 11
StatePublished - 1997

Fingerprint

Leucovorin
Paclitaxel
Fluorouracil
Breast Neoplasms
Doxorubicin
Neoplasms
Anthracyclines
Neutropenia
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer : A Vanderbilt Cancer Center phase II trial. / Nicholson, B.; Paul, D.; Shyr, Y.; Garrett, M.; Hande, K. R.; Johnson, D. H.

In: Seminars in Oncology, Vol. 24, No. 4 SUPPL. 11, 1997.

Research output: Contribution to journalArticle

Nicholson, B. ; Paul, D. ; Shyr, Y. ; Garrett, M. ; Hande, K. R. ; Johnson, D. H. / Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer : A Vanderbilt Cancer Center phase II trial. In: Seminars in Oncology. 1997 ; Vol. 24, No. 4 SUPPL. 11.
@article{cd1be5a4b65947fda66443a420e57c83,
title = "Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: A Vanderbilt Cancer Center phase II trial",
abstract = "Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenously over 30 to 60 minutes followed by 5- fluorouracil 350 mg/m2 via intravenous push on days 1 to 3 every 28 days for six cycles. Eight patients were chemotherapy naive. Of 47 previously treated women, 30 had received anthracyclines. Fifty-two patients were evaluable for response. Three (6{\%}) experienced a complete response and 24 (46{\%}) had a partial response, for an overall response rate of 52{\%}. Patients previously exposed to doxorubicin had a response rate similar to those with no prior doxorubicin exposure (50{\%} v 54{\%}, respectively). The median duration of response was 8.6 months and median survival was 17.7 months. Toxicity was modest, with grade 3 or 4 neutropenia observed in only 5.5{\%} (15 of 274) of cycles. Preliminary results indicate that paclitaxel/5- fluorouracil/leucovorin is an active, well-tolerated regimen for treating metastatic breast cancer.",
author = "B. Nicholson and D. Paul and Y. Shyr and M. Garrett and Hande, {K. R.} and Johnson, {D. H.}",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 11",

}

TY - JOUR

T1 - Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer

T2 - A Vanderbilt Cancer Center phase II trial

AU - Nicholson, B.

AU - Paul, D.

AU - Shyr, Y.

AU - Garrett, M.

AU - Hande, K. R.

AU - Johnson, D. H.

PY - 1997

Y1 - 1997

N2 - Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenously over 30 to 60 minutes followed by 5- fluorouracil 350 mg/m2 via intravenous push on days 1 to 3 every 28 days for six cycles. Eight patients were chemotherapy naive. Of 47 previously treated women, 30 had received anthracyclines. Fifty-two patients were evaluable for response. Three (6%) experienced a complete response and 24 (46%) had a partial response, for an overall response rate of 52%. Patients previously exposed to doxorubicin had a response rate similar to those with no prior doxorubicin exposure (50% v 54%, respectively). The median duration of response was 8.6 months and median survival was 17.7 months. Toxicity was modest, with grade 3 or 4 neutropenia observed in only 5.5% (15 of 274) of cycles. Preliminary results indicate that paclitaxel/5- fluorouracil/leucovorin is an active, well-tolerated regimen for treating metastatic breast cancer.

AB - Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenously over 30 to 60 minutes followed by 5- fluorouracil 350 mg/m2 via intravenous push on days 1 to 3 every 28 days for six cycles. Eight patients were chemotherapy naive. Of 47 previously treated women, 30 had received anthracyclines. Fifty-two patients were evaluable for response. Three (6%) experienced a complete response and 24 (46%) had a partial response, for an overall response rate of 52%. Patients previously exposed to doxorubicin had a response rate similar to those with no prior doxorubicin exposure (50% v 54%, respectively). The median duration of response was 8.6 months and median survival was 17.7 months. Toxicity was modest, with grade 3 or 4 neutropenia observed in only 5.5% (15 of 274) of cycles. Preliminary results indicate that paclitaxel/5- fluorouracil/leucovorin is an active, well-tolerated regimen for treating metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0030821486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030821486&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 11

ER -